← Back to Search

Other

Hi-VNI for Tracheotomy

N/A
Waitlist Available
Led By Natasha Mirza, MD
Research Sponsored by Natasha Mirza
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Scheduled to undergo elective upper airway surgery at the University of Pennsylvania
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights

Summary

The goals of this study are to establish the efficacy of Hi-VNI (High Velocity Nasal Insufflation) in upper airway surgery from the anesthesiologist's and surgeon's perspectives, and to describe the ideal patient and the ideal pathology as well as suitable clinical scenarios when this oxygenation technique should be selected.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hyperbaric oxygenation therapy

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hi-VNI as primary or adjunct oxygenation techniqueExperimental Treatment1 Intervention
Hi-VNI used as a primary or adjunct oxygenation technique during upper airway surgery
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hi-VNI
2020
N/A
~40

Find a Location

Who is running the clinical trial?

Natasha MirzaLead Sponsor
Natasha Mirza, MDPrincipal InvestigatorDepartment of Otorhinolaryngology - Head and Neck Surgery
~6 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top